Guohai Securities released a research report on April 23 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) achieving relatively rapid growth in performance; 2) focusing on shareholder returns and increasing dividends. (Mainichi Keizai Shimbun)
国海证券4月23日发布研报称，给予翔宇医疗（688626.SH）买入评级。评级理由主要包括：1）业绩实现较快增长；2）重视股东回报，分红力度加大。（每日经济新闻）
Guohai Securities released a research report on April 23 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) achieving relatively rapid growth in performance; 2) focusing on shareholder return
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.